Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
All week long we’ve been meaning to write an item about an ad we saw in which a law firm chasing Vioxx lawsuits also mentioned another drug in the same class, Pfizer’s Bextra, in the same breath—as though it were as bad.
At the time, it seemed like piling on—not that there should be anything surprising about that, coming from personal injury lawyers—because the evidence about problems associated with Bextra wasn’t nearly so damning, and it hasn’t been yanked from the market.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in